CELU
Celularity Inc. Class A Common Stock
stockNASDAQ
Celularity, Inc. headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta's unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.47 | 2026-10-12 | -20.41% | 5.148 |
| 1M | 1.31 | 2026-09-18 | -10.69% | 3.517 |
| 3M | 0.78 | 2026-07-20 | +50.00% | 5.509 |
| 6M | 1.24 | 2026-04-20 | -5.64% | 2.968 |
| 1Y | 2.00 | 2025-10-20 | -41.50% | 2.090 |
| 2Y | 2.51 | 2024-10-18 | -53.39% | — |
| 5Y | 74.60 | 2021-10-19 | -98.43% | 1.464 |
Celularity Inc. Class A Common Stock (NASDAQ:CELU) stock price today is $1.17, and today's volume is 80,414. CELU is down 6.400% today. The 30 day average volume is 149,546. CELU market cap is $37.97M with 32.45M shares outstanding.